Literature DB >> 15145339

Mitochondrial dysfunction and rod-like lesions associated with administration of beta2 adrenoceptor agonist formoterol.

Matthew C Kiernan1, Peter Bullpitt, Jane H L Chan.   

Abstract

Formoterol, a selective beta 2-adrenoceptor agonist, has been introduced recently in the treatment of poorly controlled asthma. A patient is presented who developed myalgia and muscle weakness, associated with an elevation of creatine kinase (CK) during treatment with formoterol. Subsequent muscle biopsy demonstrated atrophic fibres lacking cytochrome C-oxidase and succinate dehydrogenase, suggestive of mitochondrial dysfunction. There were no inflammatory changes. Immunocytochemical analysis using antibodies to alpha-actinin-2 and alpha-actinin-3 demonstrated positive staining of 'rod-like' bodies in atrophic fibres. Clinical and biochemical improvement occurred following withdrawal of formoterol. Possible mechanisms involved in the development of myopathy are explored.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15145339     DOI: 10.1016/j.nmd.2004.02.014

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  1 in total

1.  Cytochrome c oxidase subunit 4 isoform 2-knockout mice show reduced enzyme activity, airway hyporeactivity, and lung pathology.

Authors:  Maik Hüttemann; Icksoo Lee; Xiufeng Gao; Petr Pecina; Alena Pecinova; Jenney Liu; Siddhesh Aras; Natascha Sommer; Thomas H Sanderson; Monica Tost; Frauke Neff; Juan Antonio Aguilar-Pimentel; Lore Becker; Beatrix Naton; Birgit Rathkolb; Jan Rozman; Jack Favor; Wolfgang Hans; Cornelia Prehn; Oliver Puk; Anja Schrewe; Minxuan Sun; Heinz Höfler; Jerzy Adamski; Raffi Bekeredjian; Jochen Graw; Thure Adler; Dirk H Busch; Martin Klingenspor; Thomas Klopstock; Markus Ollert; Eckhard Wolf; Helmut Fuchs; Valérie Gailus-Durner; Martin Hrabě de Angelis; Norbert Weissmann; Jeffrey W Doan; David J P Bassett; Lawrence I Grossman
Journal:  FASEB J       Date:  2012-06-22       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.